Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06301373
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-08
First Post:
2024-01-22
Brief Title:
Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
Methotrexate Combined With Tofacitinib in the Treatment of Active Rheumatoid Arthritis With a Myeloid-stromal Pathotype a Randomized Controlled Open Label Multicenter Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rheumatoid arthritis RA is the leading cause of disability in Chinese women We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification We found that baseline myeloid stromal RA patients had severe conditions and poor outcome Early identification of synovial myeloid stromal RA patients and intensified treatment are key to improving RA efficacy
This project aims to conduct a randomized controlled open label multicenter clinical study on early intensified treatment of RA based on synovial pathology classification 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Shenshan Medical Center Memorial Hospital of Sun Yat-Sen University and Guangzhou Panyu Central Hospital They were randomly divided into an intensive treatment group and a conventional treatment group in a 11 ratio The intensive treatment group was treated with methotrexate combined with tofacitinib while the conventional treatment group was treated with methotrexate monotherapy The expected intervention period is 12 weeks with a follow-up period of 48 weeks The primary endpoint is the proportion of subjects who achieved ACR20 at week 12 Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points safety and the proportion of subjects who experienced joint destruction progression at week 48
This project proposes the concept of achieving precise diagnosis of RA based on synovial pathology classification and explores the efficacy of early methotrexate combined with tofacitinib intensified treatment for patients with synovial medullary stromal RA who have poor conventional treatment efficacy providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines
This project aims to conduct a randomized controlled open label multicenter clinical study on early intensified treatment of RA based on synovial pathology classification 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Shenshan Medical Center Memorial Hospital of Sun Yat-Sen University and Guangzhou Panyu Central Hospital They were randomly divided into an intensive treatment group and a conventional treatment group in a 11 ratio The intensive treatment group was treated with methotrexate combined with tofacitinib while the conventional treatment group was treated with methotrexate monotherapy The expected intervention period is 12 weeks with a follow-up period of 48 weeks The primary endpoint is the proportion of subjects who achieved ACR20 at week 12 Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points safety and the proportion of subjects who experienced joint destruction progression at week 48
This project proposes the concept of achieving precise diagnosis of RA based on synovial pathology classification and explores the efficacy of early methotrexate combined with tofacitinib intensified treatment for patients with synovial medullary stromal RA who have poor conventional treatment efficacy providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines
Detailed Description:
Rheumatoid arthritis RA is the leading cause of disability in Chinese women but it cannot be cured About 25-40 of RA patients experience bone erosion within 6 months after experiencing joint symptoms The first year after the onset of RA is the best window of treatment opportunity and the earlier standardized treatment is initiated the more effective RA treatment will be RA patients have strong heterogeneity and lack effective evaluation indicators for early identification of patients with poor prognosis Therefore currently domestic and foreign RA treatment guidelines do not include adverse prognostic factors in the initial stage All RA patients are recommended to start treatment with methotrexate MTX monotherapy If the improvement is not good after 3 months or does not meet the standard after 6 months csDMARDs or targeted drug biologics or JAK inhibitors should be combined However clinical studies have found that the effective rate of MTX monotherapy after 3 months is only 30 to 50 and most patients require combination therapy
The pathological basis of RA is synovitis In the early stage we established a synovial pathology cohort and proposed a new synovial immunopathology classification We found that baseline medullary stromal type 58 RA patients had severe conditions poor efficacy and a risk of joint destruction progression after 1 year of imaging was 32 times higher than other types Front Immunol 2021 Among them the efficacy of combining traditional synthetic DMARDs or biological agents for 3 months in the treatment of newly treated synovial medullary stromal RA patients is not as good as other types of patients the core criteria for RA disease activity assessment of the American Society of Rheumatology reached 20 improvement ACR20 52 vs 75 Therefore early identification of patients with synovial myeloid stromal RA and intensified treatment are key to improving the efficacy of RA
The plan for intensified treatment of RA includes the combination of MTX and biological agents or JAK inhibitors where biological agents only target specific immune cells or cytokines are expensive require intravenous medication and are prone to producing anti drug antibodies JAK inhibitors can target JAK related inflammatory pathways in different cells are convenient to take orally and do not produce anti drug antibodies The JAK inhibitors that have been listed in China include tofacitinib Barretinib and Upatinib Among them tofacitinib has the longest use time good efficacy and safety and is affordable after national centralized procurement with strong promotability
The characteristic of medullary stromal synovium is multicellular activation which can secrete inflammatory factors and a large amount of matrix metalloproteinases MMPs It has been reported that tofacitinib can inhibit the production of synovial MMP-3 Our preliminary retrospective analysis showed that in RA patients with poor efficacy of csDMARDs or biologics MTX combined with tofacitinib was used for treatment for 3 months resulting in a 56 ACR20 and a significant decrease in serum MMP-3 This suggests that MTX combined with tofacitinib can be used as an intensive treatment for synovial myeloid stromal RA patients
Based on this we propose clinical questions Synovial immunopathological classification helps to achieve accurate diagnosis of RA Can MTX combined with tofacitinib intensive treatment be applied to newly treated RA patients with synovial myeloid stromal type to achieve early disease control
This project aims to conduct a randomized controlled open label multicenter clinical study on early intensified treatment of RA based on synovial pathology classification 130 newly treated adult patients with moderate to severe active rheumatoid arthritis RA of the synovial medullary matrix type were randomly divided into an intensive treatment group and a conventional treatment group in a 11 ratio The intensive treatment group was treated with MTX combined with tofacitinib while the conventional treatment group was treated with MTX monotherapy The expected intervention period is 12 weeks with a follow-up period of 48 weeks The primary endpoint is the proportion of subjects who achieved ACR20 at week 12 Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points safety and the proportion of subjects who experienced joint destruction progression at week 48 The exploratory objective sub topic is to apply proteomics to screen serum biomarkers in patients with synovial myeloid stromal RA and establish a precise diagnostic system
This project is based on the applicants long-term research on synovial pathology of RA proposing the concept of achieving accurate diagnosis of RA based on synovial pathology classification At the same time it aims to explore the efficacy of early MTX combined with tofacitinib in patients with synovial medullary stromal RA who have poor conventional treatment efficacy providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines
The pathological basis of RA is synovitis In the early stage we established a synovial pathology cohort and proposed a new synovial immunopathology classification We found that baseline medullary stromal type 58 RA patients had severe conditions poor efficacy and a risk of joint destruction progression after 1 year of imaging was 32 times higher than other types Front Immunol 2021 Among them the efficacy of combining traditional synthetic DMARDs or biological agents for 3 months in the treatment of newly treated synovial medullary stromal RA patients is not as good as other types of patients the core criteria for RA disease activity assessment of the American Society of Rheumatology reached 20 improvement ACR20 52 vs 75 Therefore early identification of patients with synovial myeloid stromal RA and intensified treatment are key to improving the efficacy of RA
The plan for intensified treatment of RA includes the combination of MTX and biological agents or JAK inhibitors where biological agents only target specific immune cells or cytokines are expensive require intravenous medication and are prone to producing anti drug antibodies JAK inhibitors can target JAK related inflammatory pathways in different cells are convenient to take orally and do not produce anti drug antibodies The JAK inhibitors that have been listed in China include tofacitinib Barretinib and Upatinib Among them tofacitinib has the longest use time good efficacy and safety and is affordable after national centralized procurement with strong promotability
The characteristic of medullary stromal synovium is multicellular activation which can secrete inflammatory factors and a large amount of matrix metalloproteinases MMPs It has been reported that tofacitinib can inhibit the production of synovial MMP-3 Our preliminary retrospective analysis showed that in RA patients with poor efficacy of csDMARDs or biologics MTX combined with tofacitinib was used for treatment for 3 months resulting in a 56 ACR20 and a significant decrease in serum MMP-3 This suggests that MTX combined with tofacitinib can be used as an intensive treatment for synovial myeloid stromal RA patients
Based on this we propose clinical questions Synovial immunopathological classification helps to achieve accurate diagnosis of RA Can MTX combined with tofacitinib intensive treatment be applied to newly treated RA patients with synovial myeloid stromal type to achieve early disease control
This project aims to conduct a randomized controlled open label multicenter clinical study on early intensified treatment of RA based on synovial pathology classification 130 newly treated adult patients with moderate to severe active rheumatoid arthritis RA of the synovial medullary matrix type were randomly divided into an intensive treatment group and a conventional treatment group in a 11 ratio The intensive treatment group was treated with MTX combined with tofacitinib while the conventional treatment group was treated with MTX monotherapy The expected intervention period is 12 weeks with a follow-up period of 48 weeks The primary endpoint is the proportion of subjects who achieved ACR20 at week 12 Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points safety and the proportion of subjects who experienced joint destruction progression at week 48 The exploratory objective sub topic is to apply proteomics to screen serum biomarkers in patients with synovial myeloid stromal RA and establish a precise diagnostic system
This project is based on the applicants long-term research on synovial pathology of RA proposing the concept of achieving accurate diagnosis of RA based on synovial pathology classification At the same time it aims to explore the efficacy of early MTX combined with tofacitinib in patients with synovial medullary stromal RA who have poor conventional treatment efficacy providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None